Clinical Trials Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2023; 14(12): 1803-1812
Published online Dec 15, 2023. doi: 10.4239/wjd.v14.i12.1803
Relationship between GCKR gene rs780094 polymorphism and type 2 diabetes with albuminuria
Yi-Ying Liu, Qin Wan
Yi-Ying Liu, Department of Endocrinology, Deyang People’s Hospital, Deyang 618000, Sichuan Province, China
Qin Wan, Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Author contributions: Liu YY was responsible for experimental design and implementation, and paper writing; Wan Q was responsible for quality review and control.
Supported by the Key R&D Project of the Ministry of Science and Technology, No. 2016YFC0901200 and 2016YFC0901205.
Institutional review board statement: The study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University.
Clinical trial registration statement: As the study was retrospective and non-interventional, it was not clinically registered.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available from the corresponding author, Qin Wan, upon reasonable request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qin Wan, Doctor, Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou 646000, Sichuan Province, China. wanqin3@163.com
Received: September 1, 2023
Peer-review started: September 1, 2023
First decision: September 29, 2023
Revised: October 10, 2023
Accepted: November 28, 2023
Article in press: November 28, 2023
Published online: December 15, 2023
Processing time: 103 Days and 19.9 Hours
ARTICLE HIGHLIGHTS
Research background

Diabetic nephropathy (DN) is a serious complication of diabetes with no typical clinical manifestations at the beginning of the disease, and treatment efficacy is poor. Currently, it is believed that the pathogenesis of DN is associated with environmental and genetic factors. In this study, we found that CT + TT genotype in glucokinase regulatory protein (GCKR) rs780094 is a risk factor for type 2 diabetes (T2D) complicated with albuminuria.

Research motivation

Human GCKR plays an important role in sugar regulation. However, the association between GCKR gene rs780094 polymorphism and diabetes and its complications is uncertain.

Research objectives

To explore the relationship between the GCKR gene rs780094 polymorphism and T2D with albuminuria.

Research methods

The correlation between GCKR rs780094 and diabetes mellitus with proteinuria was studied by different grouping methods.

Research results

Studies have found that there are many risk factors for T2D with albuminuria. From the perspective of environmental factors, there were history of hypertension, alcohol consumption, history of hyperlipidemia, and blood glucose levels. At the genetic level, CT + TT genotype was identified to be a risk factor for T2D mellitus with albuminuria.

Research conclusions

In clinical practice, we can start with proteinuria detection, assess the risk of individuals carrying susceptibility genes, and take comprehensive prevention and control measures to delay the onset of T2D.

Research perspectives

While promising, the study has some limitations, including that it did not take into account whether patients were taking lipid-lowering and blood-pressure medications, and did not calculate insulin resistance indexes, among others. In addition, due to the limited geographical options in this study, there may be selection bias, and further clinical trials are needed to refine the conclusions of this study.